A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer - Université de Rennes Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2023

A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer

Résumé

Breast cancer is the most common cancer and the deadliest among women worldwide. Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen and progesterone receptor positive), which accounts for two-thirds of tumors. Hormone therapy using antiestrogens is the gold standard, but resistance to these treatments invariably occurs through various biological mechanisms, such as changes in estrogen receptor activity, mutations in the ESR1 gene, aberrant activation of the PI3K pathway or cell cycle dysregulations. All these factors have led to the development of new therapies, such as selective estrogen receptor degraders (SERDs), or combination therapies with cyclin-dependent kinases (CDK) 4/6 or PI3K inhibitors. Therefore, understanding the estrogen pathway is essential for the treatment and new drug development of hormone-dependent cancers. This mini-review summarizes current literature on the signalization, mechanisms of action and clinical implications of estrogen receptors in breast cancer.
Fichier principal
Vignette du fichier
ijms-24-06834.pdf (1.6 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04099814 , version 1 (17-05-2023)

Licence

Paternité

Identifiants

Citer

Léa Clusan, François Ferriere, Gilles Flouriot, Farzad Pakdel. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. International Journal of Molecular Sciences, 2023, 24 (7), pp.6834. ⟨10.3390/ijms24076834⟩. ⟨hal-04099814⟩
22 Consultations
18 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More